Quantbot Technologies LP Has $228,000 Position in Regeneron Pharmaceuticals, Inc. $REGN

Quantbot Technologies LP lessened its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 69.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 405 shares of the biopharmaceutical company’s stock after selling 902 shares during the period. Quantbot Technologies LP’s holdings in Regeneron Pharmaceuticals were worth $228,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the company. Salomon & Ludwin LLC acquired a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at about $27,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in Regeneron Pharmaceuticals during the second quarter worth approximately $31,000. Caitlin John LLC acquired a new position in Regeneron Pharmaceuticals during the third quarter worth approximately $34,000. Traub Capital Management LLC bought a new stake in Regeneron Pharmaceuticals in the second quarter valued at approximately $38,000. Finally, E Fund Management Hong Kong Co. Ltd. raised its stake in Regeneron Pharmaceuticals by 87.5% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 75 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 35 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $774.66 on Thursday. The firm has a market cap of $81.90 billion, a P/E ratio of 18.64, a price-to-earnings-growth ratio of 2.07 and a beta of 0.41. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $821.11. The business’s 50 day moving average is $770.85 and its 200-day moving average is $692.59.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business had revenue of $3.88 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the previous year, the company posted $12.07 EPS. The firm’s quarterly revenue was up 2.5% on a year-over-year basis. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were given a $0.94 dividend. The ex-dividend date of this dividend was Friday, February 20th. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.05%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, Director Huda Y. Zoghbi sold 1,638 shares of the company’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $781.33, for a total value of $1,279,818.54. Following the transaction, the director directly owned 1,703 shares in the company, valued at approximately $1,330,604.99. This represents a 49.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $778.53, for a total transaction of $77,853.00. Following the transaction, the director directly owned 17,803 shares in the company, valued at approximately $13,860,169.59. This represents a 0.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 5,274 shares of company stock valued at $4,142,738. 7.02% of the stock is currently owned by insiders.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: EU regulatory progress for Dupixent: reporting notes that the CHMP gave a positive opinion supporting Dupixent for children aged 2–11 with chronic spontaneous urticaria in the EU — a label expansion that could help sustain Dupixent revenue momentum in Europe. Sanofi’s EU Drug Wins Contrast With Weak Share Momentum And Valuation Gap
• Positive Sentiment: Corporate goodwill and brand visibility from science outreach: Regeneron’s sponsorship of the Regeneron Science Talent Search (awarding more than $1.8M) is positive for reputation and stakeholder relations — a modest supportive factor for investor sentiment. Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists
• Neutral Sentiment: Management presentations (Leerink, Barclays): Regeneron posted transcripts from recent conferences (Leerink, Barclays). These maintenances of visibility and messaging help keep investors informed about pipeline priorities (Dupixent, Libtayo, other assets) but did not introduce major new catalysts. Regeneron Presents at Leerink Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: Barclays conference transcript provides additional management commentary but no headline surprises; useful for modeling guidance and pipeline timing. Regeneron Presents at Barclays 28th Annual Global Healthcare Conference Transcript
• Neutral Sentiment: Sector roundup context: broader health‑care coverage (eczema treatments, Roche pipeline) underscores competitive dynamics in dermatology and immunology — contextually relevant to Dupixent but not an immediate Regeneron‑specific catalyst. Health Care Roundup: Market Talk
• Negative Sentiment: Analyst view warns of limited near‑term upside: a recent analysis argues REGN is “fairly valued” after a strong run and expects near‑term sideways trading because there are few immediate new revenue drivers; it also notes declining Eylea/Eylea HD sales that will need to be offset by Dupixent and future pipeline contributions. That view can cap short‑term upside despite long‑term confidence in Dupixent. Regeneron: Fairly Valued Now After A Stellar Upswing

Analyst Upgrades and Downgrades

Several research analysts have recently commented on REGN shares. Cantor Fitzgerald lifted their target price on Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the stock an “overweight” rating in a research note on Monday, February 2nd. Oppenheimer reaffirmed an “outperform” rating and set a $865.00 price target (up from $750.00) on shares of Regeneron Pharmaceuticals in a report on Monday, February 2nd. Bank of America raised shares of Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and lifted their price objective for the stock from $627.00 to $860.00 in a research report on Wednesday, January 7th. Wells Fargo & Company upped their price objective on shares of Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the company an “equal weight” rating in a report on Monday, February 2nd. Finally, Morgan Stanley increased their price objective on shares of Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the company an “equal weight” rating in a research report on Monday, February 2nd. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $802.27.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.